Previous 10 | Next 10 |
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were up 12% Wednesday afternoon, a day after the commercial-stage biotech released full-year and fourth-quarter earnings. The stock dropped as much as 17.1% on Tuesday after the earnings report, but Wednesday, it bounced back as much a...
Following an over 15% decline in the previous session, BioCryst Pharmaceuticals ( NASDAQ: BCRX ) gained ~13% on Wednesday as Needham upgraded the biotech, noting that its earnings-led selloff yesterday was an overreaction. The analyst Serge Belanger attributes the selloff to an up...
Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: BioCryst Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Conference Call February 21, 2023 08:30 ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial ...
Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q4 2022 Earnings Call Feb 21, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript
The shares of BioCryst Pharmaceuticals ( NASDAQ: BCRX ) lost ~17% to reach the lowest level since May 2022 after the maker of hereditary angioedema (HA) therapy Orladeyo announced reported a wider-than-expected loss for the December quarter. However, the company’s revenue f...
BioCryst Pharmaceuticals press release ( NASDAQ: BCRX ): Q4 Non-GAAP EPS of -$0.38 misses by $0.18 . Revenue of $79.5M (+68.4% Y/Y) beats by $5.32M . ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million. Cash, cash equivalents, restricted cash and i...
—ORLADEYO net revenue of $70.7 million for Q4 2022 and $251.6 million for FY 2022— —ORLADEYO net revenue in 2023 expected to be no less than $320 million— —ORLADEYO peak sales expected to be $1 billion— RESEARCH TRIANGLE ...
BioCryst Pharmaceuticals ( NASDAQ: BCRX ) is scheduled to announce Q4 earnings results on Tuesday, February 21st, before market open. The consensus EPS Estimate is -$0.20 (+50.0% Y/Y) and the consensus Revenue Estimate is $74.18M (+57.2% Y/Y). Over the last 1 year, BCRX has ...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...